OxyNov Inc of Québec at MEDICA 2017 in Düsseldorf -- MEDICA - World Forum for Medicine
Manufacturers OEM

OxyNov Inc

2725, Chemin Sainte-Foy, IUCPQ, Bureau Y4171, G1V 4G5 Québec

This company is co-exhibitor of
Canadian German Chamber of Industry and Commerce Inc.

Hall map

MEDICA 2017 hall map (Hall 16): stand F44

Fairground map

MEDICA 2017 fairground map: Hall 16

Our range of products

Product categories

  • 01  Electromedical equipment / Medical Technology
  • 01.04  Intense medicine / anesthesiology / respiration
  • 01.04.05  Oxygen equipment

Oxygen equipment

Our products

Product category: Oxygen equipment


FreeO2 is an oxygen therapy optimization device enabling:

  • The automatic titration of oxygen flow administered according to the target oxygen saturation level set by the clinician and according to the patient’s response (adult, child, newborn)
  • Continuous monitoring of significant cardiorespiratory parameters
  • Automated weaning from oxygen therapy
  • Use of new clinical decision-making tools

FreeO2 allows all hospital departments and units that administer oxygen therapy

  • To improve the efficacy of the treatment, as well as patient comfort and safety
  • To prevent complications related to hypoxia or hyperoxia
  • To lessen the workload of healthcare professionals
  • To reduce the length of treatment and hospitals stays

More Less

About us

Company details

Oxynov was founded at the Institut universitaire de cardiologie et de pneumologie de Québec with the support of all respirologists on staff.

Oxynov was founded in 2009 by two physician-researchers, François Lellouche (M.D., Ph.D.) and Erwan L’Her (M.D., Ph.D.), working in the field of respiratory health and conscious of the unmet needs of clinicians. OxyNov is a company focused on clinical innovation and on the marketing of its oxygen therapy devices.

Revolutionize oxygen therapy and respiratory assistance through an approach that combines medical research with technological innovation to develop a range of interrelated solutions to:

  • Improve patients’ quality of life (efficacy and safety of treatment, keeping patients at home).
  • Contribute to the effort to reduce healthcare costs.

At the beginning of 2017, OxyNov will target the European hospital market with FreeO2, a unique solution that revolutionizes oxygen therapy, the treatment most frequently administered in hospitals.

  • Ten clinical studies involving over 400 hospital patients in Canada and France demonstrated the benefits of FreeO2 for patients and for the healthcare system, including shorter hospital stays.
  • FreeO2 is protected by a U.S. patent.

More Less